{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053836","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2026-08-06T11:16:15+00:00","discovered_at":"2026-08-06T11:20:00.387184+00:00","generated_at":"2026-08-06T11:20:11.049382+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Precision BioSciences reports first clinical evidence of cccDNA elimination in HBV; Q2 net loss $32.7M","bullets":["Liver biopsy showed 1-log reduction in cccDNA with <1% remaining after two PBGENE-HBV doses.","pgRNA became undetectable in 100% of evaluable patients; sustained up to six months.","Cash balance $112.4M as of June 30, 2026; expected to fund milestones through 2028.","Net loss $32.7M ($1.26/share) vs $23.5M ($2.13/share) in Q2 2025; non-cash warrant loss drove increase.","Alex Kelly promoted to COO; Naresh Tanna promoted to CFO; Cassie Gorsuch now leads all research."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053836","json":"https://secwatch.observer/filing/0001628280-26-053836.json","markdown":"https://secwatch.observer/filing/0001628280-26-053836.md","text":"https://secwatch.observer/filing/0001628280-26-053836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/0001628280-26-053836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/dtil-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:20:11.049382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}